## Silvia Morbelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6144189/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimer's and Dementia, 2020, 16, 1305-1311.	0.8	806
2	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	7.6	636
3	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
4	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
5	Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17384-17389.	7.1	241
6	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage: Clinical, 2014, 6, 445-454.	2.7	172
7	Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology, 2014, 83, 1067-1074.	1.1	154
8	Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 251-259.	6.4	148
9	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912.	6.4	134
10	Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle, 2013, 12, 3490-3499.	2.6	124
11	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	3.1	108
12	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	5.0	108
13	Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3187-3197.	6.4	106
14	Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 36-45.	6.4	95
15	Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 565-573.	6.4	86
16	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage: Clinical, 2015, 7, 34-42.	2.7	85
17	Cognitiveâ€nigrostriatal relationships in de novo, drugâ€naÃ⁻ve Parkinson's disease patients: A [lâ€123]FPâ€CIT SPECT study. Movement Disorders, 2010, 25, 35-43.	3.9	83
18	Early identification of MCI converting to AD: a FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2042-2052.	6.4	83

#	Article	IF	CITATIONS
19	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 632-651.	6.4	82
20	The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease. Journal of Nuclear Medicine, 2018, 59, 1437-1444.	5.0	80
21	Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2191-2202.	6.4	77
22	Diabetes Impairs the Vascular Recruitment of Normal Stem Cells by Oxidant Damage, Reversed by Increases in pAMPK, Heme Oxygenase-1, and Adiponectin. Stem Cells, 2009, 27, 399-407.	3.2	75
23	<sup>18</sup> F-NaF Uptake by Atherosclerotic Plaque on PET/CT Imaging: Inverse Correlation Between Calcification Density and Mineral Metabolic Activity. Journal of Nuclear Medicine, 2015, 56, 1019-1023.	5.0	73
24	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain, 2021, 144, 278-287.	7.6	68
25	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	2.6	67
26	Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational <sup>18</sup> F-FDG PET/CT Observation. Journal of Nuclear Medicine, 2017, 58, 1638-1645.	5.0	65
27	Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study. Movement Disorders, 2009, 24, 414-421.	3.9	63
28	Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder?. Neurobiology of Aging, 2015, 36, 3300-3305.	3.1	63
29	FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology, 2019, 92, e1121-e1135.	1.1	63
30	All-trans retinoic acid skews monocyte differentiationinto interleukin-12-secreting dendritic-like cells. British Journal of Haematology, 2003, 122, 829-836.	2.5	60
31	Unawareness of Memory Deficit in Amnestic MCI: FDG-PET Findings. Journal of Alzheimer's Disease, 2010, 22, 993-1003.	2.6	59
32	Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. Parkinsonism and Related Disorders, 2016, 29, 47-53.	2.2	57
33	A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1487-1491.	6.4	56
34	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 1009-1010.	10.2	56
35	Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: A systematic review and meta-analysis. Sleep Medicine Reviews, 2018, 41, 266-274.	8.5	56
36	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	3.6	54

#	Article	IF	CITATIONS
37	Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 437-450.	6.4	54
38	Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease. Clinical Neurophysiology, 2005, 116, 364-375.	1.5	51
39	Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1326-1338.	6.4	51
40	Metformin Temporal and Localized Effects on Gut Glucose Metabolism Assessed Using <sup>18</sup> F-FDG PET in Mice. Journal of Nuclear Medicine, 2013, 54, 259-266.	5.0	50
41	Scaled Subprofile Modeling and Convolutional Neural Networks for the Identification of Parkinson's Disease in 3D Nuclear Imaging Data. International Journal of Neural Systems, 2019, 29, 1950010.	5.2	48
42	Divergent determinants of 18F–NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. International Journal of Cardiovascular Imaging, 2014, 30, 439-447.	1.5	47
43	Metabolic patterns across core features in dementia with lewy bodies. Annals of Neurology, 2019, 85, 715-725.	5.3	47
44	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: <sup>18</sup> F-FDG PET/CT Study. Journal of Nuclear Medicine, 2017, 58, 1764-1769.	5.0	44
45	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 353-357.	6.4	44
46	Comparison Between <sup>18</sup> F-FDG PET–Based and CT-Based Criteria in Non–Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Nuclear Medicine, 2020, 61, 990-998.	5.0	44
47	Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. Movement Disorders, 2017, 32, 1738-1747.	3.9	43
48	An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline. Journal of Translational Medicine, 2018, 16, 295.	4.4	43
49	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	2.6	42
50	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	3.9	42
51	MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings. Current Alzheimer Research, 2010, 7, 287-294.	1.4	41
52	Progressive Disintegration of Brain Networking from Normal Aging to Alzheimer Disease: Analysis of Independent Components of <sup>18</sup> F-FDG PET Data. Journal of Nuclear Medicine, 2017, 58, 1132-1139.	5.0	41
53	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 563-584.	6.4	41
54	Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. Human Brain Mapping, 2016, 37, 942-953.	3.6	40

#	Article	IF	CITATIONS
55	SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. Journal of Neurology, 2021, 268, 3980-3987.	3.6	40
56	Metabolic Correlates of Rey Auditory Verbal Learning Test in Elderly Subjects with Memory Complaints. Journal of Alzheimer's Disease, 2014, 39, 103-113.	2.6	39
57	Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection. Biomedicines, 2021, 9, 287.	3.2	39
58	Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1642-1651.	6.4	38
59	The Role of the Serotonergic System in REM Sleep Behavior Disorder. Sleep, 2015, 38, 1505-1509.	1.1	36
60	Predicting the transition from normal aging to Alzheimer's disease: A statistical mechanistic evaluation of FDG-PET data. Neurolmage, 2016, 141, 282-290.	4.2	36
61	A Positron Emission Tomography/Computed Tomography (PET/CT) Evaluation of Asymptomatic Abdominal Aortic Aneurysms: Another Point of View. Annals of Vascular Surgery, 2012, 26, 491-499.	0.9	35
62	High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. Rheumatology, 2013, 52, 1865-1872.	1.9	35
63	What predicts cognitive decline in de novo Parkinson's disease?. Neurobiology of Aging, 2012, 33, 1127.e11-1127.e20.	3.1	34
64	Mechanisms underlying resilience inÂageing. Nature Reviews Neuroscience, 2019, 20, 246-246.	10.2	34
65	Detection of metastatic bone lesions in breast cancer patients: Fused 18F-Fluoride-PET/MDCT has higher accuracy than MDCT. Preliminary experience. European Journal of Radiology, 2012, 81, 2632-2638.	2.6	33
66	Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain, 2018, 141, 2272-2279.	7.6	33
67	Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2209-2218.	6.4	32
68	Microembolism Versus Hemodynamic Impairment in Rosary-Like Deep Watershed Infarcts. Stroke, 2011, 42, 3138-3143.	2.0	30
69	Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain. Arthritis Research and Therapy, 2014, 16, 492.	3.5	30
70	Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 764-775.	6.4	30
71	Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223. Cancers, 2020, 12, 31.	3.7	30
72	Direct relationship between cell density and FDG uptake in asymptomatic aortic aneurysm close to surgical threshold: an in vivo and in vitro study. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 91-101.	6.4	29

#	Article	IF	CITATIONS
73	The Alzheimer's disease metabolic brain pattern in mild cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3643-3648.	4.3	29
74	18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2073-2083.	6.4	29
75	Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 6.	3.9	29
76	Increased myocardial 18F-FDG uptake as a marker of Doxorubicin-induced oxidative stress. Journal of Nuclear Cardiology, 2020, 27, 2183-2194.	2.1	29
77	Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by C-SPECT myocardial perfusion imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2256-2263.	6.4	28
78	Diagnostic utility of FDC-PET in the differential diagnosis between different forms of primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1526-1533.	6.4	28
79	Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1337-1347.	6.4	27
80	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2061-2071.	6.4	27
81	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	3.1	27
82	Utility of quantitative EEG in early Lewy body disease. Parkinsonism and Related Disorders, 2020, 75, 70-75.	2.2	27
83	Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration. Radiology, 2014, 271, 805-813.	7.3	24
84	Obligatory role of endoplasmic reticulum in brain FDG uptake. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1184-1196.	6.4	24
85	Brain 18F-DOPA PET and cognition in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1062-1070.	6.4	23
86	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging, 2019, 76, 9-17.	3.1	23
87	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	6.4	23
88	Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. Cancers, 2021, 13, 1634.	3.7	23
89	Dual-phase amyloid PET: hitting two birds with one stone. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1300-1303.	6.4	22
90	Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis. Journal of Alzheimer's Disease, 2016, 54, 1437-1457.	2.6	22

#	Article	IF	CITATIONS
91	Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD). Alzheimer's Research and Therapy, 2018, 10, 35.	6.2	22
92	G6Pase location in the endoplasmic reticulum: Implications on compartmental analysis of FDG uptake in cancer cells. Scientific Reports, 2019, 9, 2794.	3.3	22
93	Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2834-2845.	6.4	22
94	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. Experimental Hematology, 2010, 38, 968-977.	0.4	21
95	Seizures Can Precede Cognitive Symptoms in Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 737-742.	2.6	21
96	Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2486-2499.	6.4	21
97	Stroop interference task and single-photon emission tomography in anorexia: A preliminary report. International Journal of Eating Disorders, 2005, 38, 323-329.	4.0	20
98	Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Future Oncology, 2019, 15, 13-19.	2.4	20
99	Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 334-347.	6.4	20
100	Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD). Journal of the Neurological Sciences, 2011, 310, 31-35.	0.6	19
101	Metabolic Network Abnormalities in Drugâ€NaÃ⁻ve Parkinson's Disease. Movement Disorders, 2020, 35, 587-594.	3.9	19
102	Two high-rate pentose-phosphate pathways in cancer cells. Scientific Reports, 2020, 10, 22111.	3.3	19
103	The fate of patients with REM sleep behavior disorder and mild cognitive impairment. Sleep Medicine, 2021, 79, 205-210.	1.6	19
104	Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications. Journal of Endocrinological Investigation, 2017, 40, 417-424.	3.3	18
105	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). NeuroImage: Clinical, 2019, 23, 101846.	2.7	18
106	COVID-19 and the brain: impact on nuclear medicine in neurology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2487-2492.	6.4	18
107	18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. Nuklearmedizin - NuclearMedicine, 2015, 54, 163-172.	0.7	18
108	Optimization of flow reserve measurement using SPECT technology to evaluate the determinants of coronary microvascular dysfunction in diabetes. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 357-367.	6.4	17

#	Article	IF	CITATIONS
109	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Biology of Blood and Marrow Transplantation, 2018, 24, 2501-2508.	2.0	17
110	Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Research, 2020, 10, 23.	2.5	17
111	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers, 2021, 13, 3117.	3.7	17
112	Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?. World Journal of Radiology, 2017, 9, 27.	1.1	17
113	The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [1231]FP-CIT SPECT imaging. EJNMMI Research, 2017, 7, 10.	2.5	16
114	Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease. Cortex, 2020, 130, 401-412.	2.4	16
115	Alzheimer's disease markers from structural MRI and FDG-PET brain images. European Physical Journal Plus, 2012, 127, 1.	2.6	15
116	Long COVID and the brain network of Proust's madeleine: targeting the olfactory pathway. Clinical Microbiology and Infection, 2021, 27, 1196-1198.	6.0	15
117	Mechanisms underlying the predictive power of high skeletal muscle uptake of FDG in amyotrophic lateral sclerosis. EJNMMI Research, 2020, 10, 76.	2.5	15
118	Correlation between thoracic aorta 18F-natrium fluoride uptake and cardiovascular risk. World Journal of Radiology, 2016, 8, 82.	1.1	15
119	Effect of starvation on brain glucose metabolism and 18F-2-fluoro-2-deoxyglucose uptake: an experimental in-vivo and ex-vivo study. EJNMMI Research, 2018, 8, 44.	2.5	14
120	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	2.6	14
121	From early limbic inflammation to long COVID sequelae. Brain, 2021, 144, e65-e65.	7.6	14
122	New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases. Current Medicinal Chemistry, 2018, 25, 3105-3130.	2.4	14
123	2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3599-3606.	6.4	14
124	Whole-Body Evaluation of MIBG Tissue Extraction in a Mouse Model of Long-Lasting Type II Diabetes and Its Relationship with Norepinephrine Transport Protein Concentration. Journal of Nuclear Medicine, 2008, 49, 1701-1706.	5.0	13
125	FDG uptake tracks the oxidative damage in diabetic skeletal muscle: An experimental study. Molecular Metabolism, 2020, 31, 98-108.	6.5	13
126	Comparisons between glucose analogue 2-deoxy-2-( <sup>18</sup> F)fluoro-D-glucose and <sup>18</sup> F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions. World Journal of Radiology, 2016, 8, 200.	1.1	13

#	Article	IF	CITATIONS
127	Cognitive reserve and clinical expression of Alzheimer's disease: evidence and implications for brain PET imaging. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 239-47.	1.0	13
128	Comparative diagnostic accuracy of <sup>18</sup> F-FDG PET/CT for breast cancer recurrence. Breast Cancer: Targets and Therapy, 2017, Volume 9, 461-471.	1.8	12
129	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 229-239.	2.8	12
130	Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1263-1274.	6.4	12
131	Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. Nuclear Medicine and Biology, 2015, 42, 858-863.	0.6	11
132	A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility. Diagnostics, 2017, 7, 57.	2.6	11
133	The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease. Neurobiology of Aging, 2020, 96, 117-127.	3.1	11
134	Beyond Covid-19 vaccination-associated pitfalls on [18F]Fluorodeoxyglucose (FDG) PET: a case of a concomitant sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2661-2662.	6.4	11
135	18F-fluoro-2-deoxy-d-glucose (FDG) uptake. What are we looking at?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1278-1286.	6.4	11
136	Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1939.	6.4	11
137	Global cognitive impairment should be taken into account in SPECT–neuropsychology correlations: the example of verbal memory in very mild Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1186-1192.	6.4	10
138	Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography. Cancer Imaging, 2014, 14, 10.	2.8	10
139	Imaging biomarkers in Alzheimer's disease: added value in the clinical setting. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 360-371.	0.7	10
140	The Role of Endoplasmic Reticulum in the Differential Endurance against Redox Stress in Cortical and Spinal Astrocytes from the Newborn SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Antioxidants, 2021, 10, 1392.	5.1	10
141	Metformin and cancer: Technical and clinical implications for FDG-PET imaging. World Journal of Radiology, 2015, 7, 57.	1.1	10
142	Clinical images: The multifaceted pathogenesis of polymyalgia rheumatica/giant cell arteritis. Arthritis and Rheumatism, 2009, 60, 2771-2771.	6.7	9
143	1,25-Dihydroxy vitamin D and coronary microvascular function. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 280-289.	6.4	9
144	Resting metabolic connectivity in Alzheimer's disease. Clinical and Translational Imaging, 2013, 1, 271-278.	2.1	9

#	Article	IF	CITATIONS
145	ls dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1056-1059.	6.4	9
146	Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 232-239.	6.4	9
147	Rapid eye movement sleep behavior disorder: A proofâ€ofâ€concept neuroprotection study for prodromal synucleinopathies. European Journal of Neurology, 2021, 28, 1210-1217.	3.3	9
148	The Reversed Clock Drawing Test Phenomenon in Alzheimer's Disease: A Perfusion SPECT Study. Dementia and Geriatric Cognitive Disorders, 2010, 29, 1-10.	1.5	8
149	Intrabone Transplant of Cord Blood Stem Cells Establishes a Local Engraftment Store: A Functional PET/FDG Study. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-8.	3.0	8
150	Tissue specificity in fasting glucose utilization in slightly obese diabetic patients submitted to bariatric surgery. Obesity, 2013, 21, E175-81.	3.0	8
151	Neuroimaging features inC9orf72andTARDBPdouble mutation with FTD phenotype. Neurocase, 2015, 21, 529-534.	0.6	8
152	Frontal Variant Alzheimer Disease or Frontotemporal Lobe Degeneration With Incidental Amyloidosis?. Alzheimer Disease and Associated Disorders, 2016, 30, 183-185.	1.3	8
153	Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology. Medicina (Lithuania), 2020, 56, 373.	2.0	8
154	The Elusive Link Between Cancer FDG Uptake and Glycolytic Flux Explains the Preserved Diagnostic Accuracy of PET/CT in Diabetes. Translational Oncology, 2020, 13, 100752.	3.7	8
155	Longitudinal analysis of atherosclerotic plaques evolution: an 18F-NaF PET/CT study. Journal of Nuclear Cardiology, 2022, 29, 1713-1723.	2.1	8
156	Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers. Methods in Molecular Biology, 2018, 1750, 203-212.	0.9	8
157	Amyloid positron emission tomography and cognitive reserve. World Journal of Radiology, 2015, 7, 475.	1.1	8
158	Whole Body and Cardiac Metaiodobenzylguanidine Kinetics in Parkinson Disease and Multiple System Atrophy. Clinical Nuclear Medicine, 2010, 35, 311-316.	1.3	7
159	18F-FDG-PET and MRI in autoimmune encephalitis: a systematic review of brain findings. Clinical and Translational Imaging, 2018, 6, 151-168.	2.1	7
160	Could arterial spin labelling perfusion imaging uncover the invisible in <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate receptor encephalitis?. European Journal of Neurology, 2019, 26, e86-e87.	3.3	7
161	A new frontier for amyloid PET imaging: multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 276-279.	6.4	7
162	Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 2293-2302.	3.9	7

#	Article	IF	CITATIONS
163	Stratification Tools for Diseaseâ€Modifying Trials in Prodromal Synucleinopathy. Movement Disorders, 2022, 37, 52-61.	3.9	7
164	Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study. Cancers, 2022, 14, 1744.	3.7	7
165	Orbitofrontal <sup><b>18</b></sup> F-DOPA Uptake and Movement Preparation in Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-7.	1.1	6
166	Bilateral motor and premotor cortex hypometabolism in a case of Mills syndrome. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 414-417.	1.7	6
167	18F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress. International Journal of Molecular Sciences, 2020, 21, 8154.	4.1	6
168	Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools. EJNMMI Research, 2020, 10, 137.	2.5	6
169	Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223. Annals of Nuclear Medicine, 2022, 36, 373-383.	2.2	6
170	Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker. Journal of Alzheimer's Disease, 2019, 72, 1193-1207.	2.6	5
171	FDG-PET Imaging of Doxorubicin-Induced Cardiotoxicity: a New Window on an Old Problem. Current Cardiovascular Imaging Reports, 2019, 12, 1.	0.6	5
172	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€DLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.8	5
173	Dual-point FDG-PET/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 176-184.	1.0	5
174	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of Endocrinological Investigation, 2017, 40, 1265-1269.	3.3	4
175	Education-Adjusted Normality Thresholds for FDG-PET in the Diagnosis of Alzheimer Disease. Neurodegenerative Diseases, 2018, 18, 120-126.	1.4	4
176	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2021, 17, 1186-1194.	1.4	4
177	Prolonged complete remission after induction chemotherapy followed by chemoradiation with tomotherapy in metastatic nasopharyngeal cancer. Anticancer Research, 2014, 34, 5075-8.	1.1	4
178	Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management. Diagnostics, 2022, 12, 581.	2.6	4
179	Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data. Neurobiology of Aging, 2022, 117, 212-221.	3.1	4
180	A comparison of advanced semi-quantitative amyloid PET analysis methods. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4097-4108.	6.4	4

#	Article	IF	CITATIONS
181	Witnessing ischemia or proofing coronary atherosclerosis: two different windows on the same or on different pathways precipitating cardiovascular events?. Journal of Nuclear Cardiology, 2009, 16, 447-455.	2.1	3
182	Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis. Journal of Endocrinological Investigation, 2014, 37, 1099-1108.	3.3	3
183	Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives. Bioengineering, 2018, 5, 58.	3.5	3
184	Role of [18F]-FDG PET in patients with atypical parkinsonism associated with dementia. Clinical and Translational Imaging, 2020, 8, 107-122.	2.1	3
185	Probing the Role of a Regional Quantitative Assessment of Amyloid PET. Journal of Alzheimer's Disease, 2021, 80, 383-396.	2.6	3
186	FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration. Clinical Nuclear Medicine, 2021, 46, e327-e328.	1.3	3
187	Phase and amplitude electroencephalography correlations change with disease progression in people with idiopathic rapid eye-movement sleep behavior disorder. Sleep, 2022, 45, .	1.1	3
188	Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). Diagnostics, 2021, 11, 108.	2.6	3
189	Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3878-3891.	6.4	3
190	Differentiated thyroid cancer incidentally detected by 18F-FDG PET/CT: patient's future in a hot-spot?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1479-1481.	6.4	2
191	Electroconvulsive Therapy in a Patient With Chronic Catatonia. Journal of ECT, 2016, 32, 222-223.	0.6	2
192	<sup>18</sup> F-Fluorodeoxyglucose Imaging of Inflammation. Circulation: Cardiovascular Imaging, 2017, 10, e006185.	2.6	2
193	Polysomnographic correlates of sleep disturbances in de novo, drug naÃ⁻ve Parkinson's Disease. Neurological Sciences, 2021, , 1.	1.9	2
194	Neuroimaging Findings in Mild Cognitive Impairment. , 2014, , 271-307.		2
195	123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies. European Radiology Experimental, 2020, 4, 27.	3.4	2
196	Metabolic and densitometric correlation between atherosclerotic plaque and trabecular bone: an F-Natrium-Fluoride PET/CT study. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 387-396.	1.0	2
197	Mitochondrial Generated Redox Stress Differently Affects the Endoplasmic Reticulum of Circulating Lymphocytes and Monocytes in Treatment-NaÃ⁻ve Hodgkin's Lymphoma. Antioxidants, 2022, 11, 762.	5.1	2
198	Skeletal Involvement in Infants with Neuroblastoma a Quality Control Attempt. Tumori, 2007, 93, 82-87.	1.1	1

#	Article	IF	CITATIONS
199	Radionuclide imaging of subendocardial ischaemia: an insight into coronary pathophysiology or a technical artefact?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 861-865.	6.4	1
200	Reply: Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: Are There Unsuspected Confounders?. Journal of Nuclear Medicine, 2018, 59, 713.2-714.	5.0	1
201	Prevention of systemic toxicity in hyperthermic isolated lung perfusion using radioisotopic leakage monitoring. International Journal of Hyperthermia, 2018, 34, 469-478.	2.5	1
202	Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review. Clinical and Translational Imaging, 2019, 7, 159-170.	2.1	1
203	18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease. , 2019, , 37-48.		1
204	Amyloid PET in the diagnostic workup of neurodegenerative disease. Clinical and Translational Imaging, 2021, 9, 383-397.	2.1	1
205	Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study. Biomedicines, 2021, 9, 971.	3.2	1
206	Novel PET Tracers in the Management of Cardiac Sarcoidosis. Current Radiopharmaceuticals, 2021, 14, 220-227.	0.8	1
207	Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach. Medicina (Lithuania), 2021, 57, 975.	2.0	1
208	Evaluation of Age and Sex-Related Metabolic Changes in Healthy Subjects: An Italian Brain 18F-FDG PET Study. Journal of Clinical Medicine, 2021, 10, 4932.	2.4	1
209	Two-way crossed cerebellar diaschisis in a clinically isolated syndrome suggestive of multiple sclerosis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 225-226.	0.7	1
210	18F-FDG-PET correlates of aging and disease course in ALS as revealed by distinct PVC approaches. European Journal of Radiology Open, 2022, 9, 100394.	1.6	1
211	Cardiac and aortic involvement in patients with polymyalgia rheumatica: a study with echocardiography and FDG-PET/CT. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 224.	0.8	1
212	Spleen Perfusion as an Index of Gender Impact on Sympathetic Nervous System Response to Exercise. Frontiers in Physiology, 2021, 12, 780713.	2.8	1
213	The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1945-1955.	2.8	1
214	Brain perfusion SPECT provides new insight on neurobiological effects of hyperbaric hyperoxia. Acta Physiologica, 2013, 209, 5-6.	3.8	0
215	What can PET scans tell us about the effect of education on Alzheimer's disease patients?. Imaging in Medicine, 2013, 5, 391-393.	0.0	0
216	Polymyalgia rheumatica or lymphoma recurrence? Positron emission tomography/computed tomography is a specific imaging technique that helps differential diagnosis. Rheumatology, 2014, 53, 809-809.	1.9	0

#	Article	IF	CITATIONS
217	P4-190: 18FDG PET Predicts Time to Disease Milestones in a Naturalistic Population of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease. , 2016, 12, P1094-P1095.		0
218	Radionuclide Imaging of Cardiovascular Disease. , 2019, , 449-497.		0
219	The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lungÂcancer (NSCLC). Clinical and Translational Imaging, 2020, 8, 29-38.	2.1	0
220	Multimodal approach in the preâ€surgical evaluation of focal epilepsy surgery candidates: how far are we from a nonâ€invasive ESlâ€based "sourcectomyâ€?. Epileptic Disorders, 2021, 23, 661-666.	1.3	0
221	Sex differences in neuroimaging biomarkers in healthy subjects and dementia. , 2021, , 125-162.		0
222	Increased 68ÂGa-PSMA-11 Bone Marrow and Splenic Uptake in a Case of Erythroid Myelodysplasia. Nuclear Medicine and Molecular Imaging, 2021, 55, 323-324.	1.0	0
223	Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 83-92.	0.7	0
224	Evidence-Based PET for Neurological Diseases. , 2020, , 125-136.		0
225	PET imaging in dementia. , 2021, , .		0
226	Central Nervous System Imaging in Movement Disorders. , 2021, , .		0
227	Advances in Lung Cancer Imaging and Therapy. Cancers, 2022, 14, 58.	3.7	0

228 Brain Imaging. , 2015, , .

0